Mitoimmune Therapeutics

Biotechnology Research • 108, Bongeunsa-ro, Korea, Republic of • 1-10 Employees

Company overview

Headquarters	108, Bongeunsa-ro, Korea, Republic of
Phone number	+82269336726
Website	mitoimmune.com
NAICS	541714
Founded	2018
Employees	1-10
Socials

Key Contact at Mitoimmune Therapeutics

Choong Hee Lee

Director Of Clinical Team

About Mitoimmune Therapeutics

MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches. Our molecules based on the MIT platform are basically mitochondria-targeted ferroptosis inhibitors which have been demonstrated to recover intracellular homeostasis of iron, calcium, redox, and immune and to preserve antioxidant systems such as GPX4 under pathological conditions where an abnormal increase of mitochondrial reactive oxygen species (ROS) and the accumulation of calcium and iron accumulation occur.

Mitoimmune Therapeutics revenue & valuation

Annual revenue	$513,330
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,700,000
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

Mitoimmune Therapeutics has never raised funding before.